

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Ken Fujise et al.

Serial No.: 10/021,753

Filed: October 30, 2001

For: METHODS AND COMPOSITIONS
RELATING TO FORTILIN, AN ANTI-
APOPTOTIC MOLECULE, AND
MODULATORS OF FORTILIN

Group Art Unit: 1635

Examiner: Jon E. Angell

Atty. Dkt. No.: UTSH:251US

Confirmation No.: 6306

CERTIFICATE OF ELECTRONIC SUBMISSION

DATE OF SUBMISSION: November 7, 2006

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. § 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed. If an appropriate check has not been enclosed, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/UTSH:251US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,


Gina M. Shishima
Reg. No. 45,104
Attorney for Applicants
Pg No. 37, 642

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: November 7, 2006

| | | | |
|---|---|---------------------------------------|--------------------------|
| Form PTO-1449 (modified) | | Atty. Docket No. UTSH:251US | Serial No. 10/021,753 |
| List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant Ken Fujise <i>et al.</i> | |
| | | Filing Date: October 30, 2001 | Group: 1635 |
| U.S. Patent Documents <i>See Page 1</i> | Foreign Patent Documents <i>See Page 1</i> | Other Art <i>See Page 1</i> | |

U.S. Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Name | Class | Sub Class | Filing Date of App. |
|-------------|-----------|-----------------|------|------|-------|-----------|---------------------|
| | | | | | | | |

Foreign Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Country | Language |
|-------------|-----------|-----------------|----------|---------|----------|
| | B1 | WO 01/18046 | 03/15/01 | WIPO | English |
| | B2 | WO 94/12881 | 06/09/94 | WIPO | English |
| | B3 | WO 98/04291 | 02/05/98 | WIPO | English |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C19 | Gachet <i>et al.</i> , "The growth-related translationally controlled protein p23 has properties of a tubulin binding protein and associates transiently with microtubules during the cell cycle," <i>Journal of Cell Science</i> , 112:1257-1271, 1999. |
| | C20 | Sinha <i>et al.</i> , "Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis," <i>Electrophoresis</i> , 21: 3048-3057, 2000. |

25689048.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)